https://www.selleckchem.com/pr....oducts/2-deoxy-d-glu
Results will be immunobridged to historical cohorts of girls and young women in whom efficacy has been demonstrated. This is the first randomised trial of the single dose HPV vaccine schedule in the target age group. The trial will allow us to examine the quality and durability of immune responses of reduced dose schedules in a population with high burden of malaria and other infections that may affect vaccine immune responses. Initial results (24months) are expected to be published in early 2021. This is the first randomised
Like
Comment
Share
